1187 related articles for article (PubMed ID: 12473604)
21. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2.
Correale P; Micheli L; Vecchio MT; Sabatino M; Petrioli R; Pozzessere D; Marsili S; Giorgi G; Lozzi L; Neri P; Francini G
Br J Cancer; 2001 Nov; 85(11):1722-30. PubMed ID: 11742494
[TBL] [Abstract][Full Text] [Related]
22. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
[TBL] [Abstract][Full Text] [Related]
23. Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24.
Tanaka F; Fujie T; Tahara K; Mori M; Takesako K; Sette A; Celis E; Akiyoshi T
Cancer Res; 1997 Oct; 57(20):4465-8. PubMed ID: 9377553
[TBL] [Abstract][Full Text] [Related]
24. Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy.
Suda T; Tsunoda T; Daigo Y; Nakamura Y; Tahara H
Cancer Sci; 2007 Nov; 98(11):1803-8. PubMed ID: 17784873
[TBL] [Abstract][Full Text] [Related]
25. Identification of an HLA-A24-restricted OY-TES-1 epitope recognized by cytotoxic T-cells.
Okumura H; Noguchi Y; Uenaka A; Aji T; Ono T; Nakagawa K; Aoe M; Shimizu N; Nakayama E
Microbiol Immunol; 2005; 49(11):1009-16. PubMed ID: 16301813
[TBL] [Abstract][Full Text] [Related]
26. The in vitro generation of Ph1+ ALL-specific HLA-A24-restricted cytotoxic T lymphocytes using a synthetic 16 mer minor bcr-abl peptide.
Hagihara M; Tsuchiya T; Hyodo O; Ueda Y; Tazume K; Gansuvd B; Kato S; Hotta T
Leuk Res; 2003 Mar; 27(3):253-7. PubMed ID: 12537978
[TBL] [Abstract][Full Text] [Related]
27. Prostate-related antigen-derived new peptides having the capacity of inducing prostate cancer-reactive CTLs in HLA-A2+ prostate cancer patients.
Harada M; Matsueda S; Yao A; Ogata R; Noguchi M; Itoh K
Oncol Rep; 2004 Sep; 12(3):601-7. PubMed ID: 15289844
[TBL] [Abstract][Full Text] [Related]
28. A novel cytotoxic T-cell epitope presented by HLA-A24 molecule in hepatitis C virus infection.
Kurokohchi K; Arima K; Nishioka M
J Hepatol; 2001 Jun; 34(6):930-5. PubMed ID: 11451179
[TBL] [Abstract][Full Text] [Related]
29. Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles.
Matsueda S; Takedatsu H; Yao A; Tanaka M; Noguchi M; Itoh K; Harada M
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6933-43. PubMed ID: 16203785
[TBL] [Abstract][Full Text] [Related]
30. Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen.
Lu J; Celis E
Cancer Res; 2002 Oct; 62(20):5807-12. PubMed ID: 12384542
[TBL] [Abstract][Full Text] [Related]
31. Identification of parathyroid hormone-related protein-derived peptides immunogenic in human histocompatibility leukocyte antigen-A24+ prostate cancer patients.
Yao A; Harada M; Matsueda S; Ishihara Y; Shomura H; Noguchi M; Matsuoka K; Hara I; Kamidono S; Itoh K
Br J Cancer; 2004 Jul; 91(2):287-96. PubMed ID: 15199397
[TBL] [Abstract][Full Text] [Related]
32. Identification of HLA-A24 restricted shared antigen recognized by autologous cytotoxic T lymphocytes from a patient with large cell carcinoma of the lung.
Sugaya M; Takenoyama M; Shigematsu Y; Baba T; Fukuyama T; Nagata Y; Mizukami M; So T; Ichiki Y; Yasuda M; So T; Hanagiri T; Sugio K; Yasumoto K
Int J Cancer; 2007 Mar; 120(5):1055-62. PubMed ID: 17131342
[TBL] [Abstract][Full Text] [Related]
33. Identification of novel MAGE-A6- and MAGE-A12-derived HLA-A24-restricted cytotoxic T lymphocyte epitopes using an in silico peptide-docking assay.
Akiyama Y; Komiyama M; Nakamura Y; Iizuka A; Oshita C; Kume A; Nogami M; Miyata H; Ashizawa T; Yoshikawa S; Kiyohara Y; Yamaguchi K
Cancer Immunol Immunother; 2012 Dec; 61(12):2311-9. PubMed ID: 22707303
[TBL] [Abstract][Full Text] [Related]
34. Evidence for cytotoxic T lymphocyte response against human lung cancer: reconstitution of antigenic epitope with peptide eluted from lung adenocarcinoma MHC class I.
Calhoun RF; Naziruddin B; Enriquez-Rincon F; Duffy BF; Ritter JM; Sundaresan S; Patterson GA; Cooper JD; Mohanakumar T
Surgery; 2000 Jul; 128(1):76-85. PubMed ID: 10876189
[TBL] [Abstract][Full Text] [Related]
35. Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment.
Scheibenbogen C; Sun Y; Keilholz U; Song M; Stevanovic S; Asemissen AM; Nagorsen D; Thiel E; Rammensee HG; Schadendorf D
Int J Cancer; 2002 Mar; 98(3):409-14. PubMed ID: 11920592
[TBL] [Abstract][Full Text] [Related]
36. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses.
Nouri-Shirazi M; Banchereau J; Bell D; Burkeholder S; Kraus ET; Davoust J; Palucka KA
J Immunol; 2000 Oct; 165(7):3797-803. PubMed ID: 11034385
[TBL] [Abstract][Full Text] [Related]
37. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729
[TBL] [Abstract][Full Text] [Related]
38. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide.
Correale P; Walmsley K; Zaremba S; Zhu M; Schlom J; Tsang KY
J Immunol; 1998 Sep; 161(6):3186-94. PubMed ID: 9743387
[TBL] [Abstract][Full Text] [Related]
39. In vitro induction of HLA-A2402-restricted and carcinoembryonic-antigen-specific cytotoxic T lymphocytes on fixed autologous peripheral blood cells.
Kim C; Matsumura M; Saijo K; Ohno T
Cancer Immunol Immunother; 1998 Oct; 47(2):90-6. PubMed ID: 9769117
[TBL] [Abstract][Full Text] [Related]
40. Aberrant expression and potency as a cancer immunotherapy target of alpha-methylacyl-coenzyme A racemase in prostate cancer.
Honma I; Torigoe T; Hirohashi Y; Kitamura H; Sato E; Masumori N; Tamura Y; Tsukamoto T; Sato N
J Transl Med; 2009 Dec; 7():103. PubMed ID: 20003233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
